Login to Your Account

Amgen Wins Oncology Label For Aranesp Against Anemia

By Randall Osborne

Tuesday, July 23, 2002
Amgen Inc.'s Aranesp (darbepoetin alpha) for oncology applications won FDA approval, and the competitive race that began last year between the company and erythropoietin licensee Johnson & Johnson will begin heating up shortly. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription